Group 1 - The company Beijing Kexing Holdings (Group) Co., Ltd. has recently received a drug re-registration approval notice for its self-developed combined vaccine for hepatitis A and B, named Beirlaifu® [2] - Beirlaifu® is designed for both children and adults, with the children's formulation suitable for ages 1-15 and the adult formulation for those aged 16 and above who are at risk of hepatitis A and B infections [2] - Viral hepatitis, particularly hepatitis A (HAV) and hepatitis B (HBV), poses a significant public health threat in China and globally, with a notable shift in the age demographic of hepatitis A cases indicating a large immunity gap among adults [2] Group 2 - The vaccine industry is experiencing intensified competition, with innovation becoming a focal point for development [3] - The company is building a research and development platform focused on innovative product development, with over 20 vaccine and antibody products currently in the pipeline [3] - The company plans to expand its product matrix to include vaccines and antibodies targeting respiratory diseases, intestinal infectious diseases, wound infections, and vector-borne diseases, with an expectation to obtain approval for 9 products by 2030 [3]